Phase II Multicenter, Open‐Label Study of Oral ENMD‐2076 for the Treatment of Patients with Advanced Fibrolamellar Carcinoma

LESSONS LEARNED: The fibrolamellar carcinoma‐associated DNAJB1‐PRKACA gene fusion transcript RNA codes for the catalytic domain of protein kinase A and, thus, overexpression of Aurora kinase A. ENMD‐2076 showed a favorable toxicity profile. The limited results, one patient (3%) with a partial respon...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncologist
Autors principals: Abou‐Alfa, Ghassan K., Mayer, Robert, Venook, Alan P., O'Neill, Allison F., Beg, Muhammad S., LaQuaglia, Michael, Kingham, Peter T., Kobos, Rachel, Basturk, Olca, Brennan, Cameron, Yopp, Adam, Harding, James J., Leong, Stephen, Crown, John, Hoti, Emir, Leonard, Gregory, Ly, Michele, Bradley, Mikaela, Valentino, Emily, Markowitz, David, Zukiwski, Alexander, Ren, Ken, Gordan, John D.
Format: Artigo
Idioma:Inglês
Publicat: John Wiley & Sons, Inc. 2020
Matèries:
Clinical Trial Results
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8186410/
https://ncbi.nlm.nih.gov/pubmed/32154962
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2020-0093
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars